Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Valenti

Showing results (101-110 of 439) with videos related to

Pageof 44
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|July 28, 2025
Response to Letter to the Editor: "Advancing TMPRSS6-Targeted Therapy for MASLD: Mechanistic and Translational Perspectives"Mariateresa Pettinato, Alessia Pagani, Antonella Nai, et al.
NPJ Genomic Medicine|October 16, 2023
Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databasesOmid Seidizadeh, Andrea Cairo, Luciano Baronciani, et al.
Journal of Medicinal Food|October 1, 2013
The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver diseaseValerio Nobili, Giorgio Bedogni, Benedetta Donati, et al.
Hepatology (Baltimore, Md.)|May 19, 2015
ReplyStefano Romeo, Alessio Aghemo, Thomas Berg, et al.
Clinical Chemistry and Laboratory Medicine|November 16, 2013
Hepcidin levels in chronic hemodialysis patients: a critical evaluationLuca Valenti, Piergiorgio Messa, Serena Pelusi, et al.
Journal of Hepatology|March 7, 2021
Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease"Oveis Jamialahmadi, Cristiana Bianco, Serena Pelusi, et al.
Hepatology (Baltimore, Md.)|March 15, 2020
Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems BiologySilvia Sookoian, Carlos J Pirola, Luca Valenti, et al.
Annual Review of Medicine|January 27, 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis: Therapeutic Options and Approaches to TreatmentMonica A Tincopa, Elizabeth K Speliotes, Luca Valenti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 21, 2021
COVID-19 and the liver: A 2021 updateCatherine W Spearman, Alessio Aghemo, Luca Valenti, et al.
Internal and Emergency Medicine|November 5, 2008
Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?Luca Valenti, Anna Ludovica Fracanzani, Paola Dongiovanni, et al.
Pageof 44

Showing results (101-110 of 439) with videos related to

Sort By:
Pageof 44
Liver International : Official Journal of the International Association for the Study of the Liver|July 28, 2025
Response to Letter to the Editor: "Advancing TMPRSS6-Targeted Therapy for MASLD: Mechanistic and Translational Perspectives"Mariateresa Pettinato, Alessia Pagani, Antonella Nai, et al.
NPJ Genomic Medicine|October 16, 2023
Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databasesOmid Seidizadeh, Andrea Cairo, Luciano Baronciani, et al.
Journal of Medicinal Food|October 1, 2013
The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver diseaseValerio Nobili, Giorgio Bedogni, Benedetta Donati, et al.
Hepatology (Baltimore, Md.)|May 19, 2015
ReplyStefano Romeo, Alessio Aghemo, Thomas Berg, et al.
Clinical Chemistry and Laboratory Medicine|November 16, 2013
Hepcidin levels in chronic hemodialysis patients: a critical evaluationLuca Valenti, Piergiorgio Messa, Serena Pelusi, et al.
Journal of Hepatology|March 7, 2021
Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease"Oveis Jamialahmadi, Cristiana Bianco, Serena Pelusi, et al.
Hepatology (Baltimore, Md.)|March 15, 2020
Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems BiologySilvia Sookoian, Carlos J Pirola, Luca Valenti, et al.
Annual Review of Medicine|January 27, 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis: Therapeutic Options and Approaches to TreatmentMonica A Tincopa, Elizabeth K Speliotes, Luca Valenti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 21, 2021
COVID-19 and the liver: A 2021 updateCatherine W Spearman, Alessio Aghemo, Luca Valenti, et al.
Internal and Emergency Medicine|November 5, 2008
Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?Luca Valenti, Anna Ludovica Fracanzani, Paola Dongiovanni, et al.
Pageof 44